Using BRCA1 methylation (BRCAness) as a predictor for therapeutic response to PARP inhibitors and other therapeutics, will allow direct triple negative breast cancer treatment without previous screening for BRCA1 mutations. This methodological setup will facilitate the faster decision toward the use of newest medicaments to increase cells’ susceptibility to apoptosis and cancer cell diminishment.
Members of the Department of Molecular Biology received the project "Targeted rewriting of epigenetic marks as a new therapeutic approach in triple negative breast cancer cells" in collaboration with colleagues from the German Cancer Research Center funded by the Alexander von Humboldt Foundation for 2 years. This is also the topic of the doctoral thesis of Ana Sarić, a research trainee at the Department of Molecular Biology.
Address
Bulevar despota Stefana 142
11108 Belgrade
Serbia
Contact
Telefon: +381 11 20 78 300
Fax: +381 11 27 61 433
Email: ibiss@ibiss.bg.ac.rs
